top of page

Epygenix Therapeutics has been acquired by Harmony Biosciences, a pharmaceutical company dedicated to developing and commercializing

innovative therapies for patients with rare neurological diseases. For more information on Harmony and the acquisition, please click here
The Argus Trial is continuing uninterrupted with Harmony Biosciences.

Innovative
science.
Steadfast
commitment.

We’re redefining rare epilepsy drug research.

Max

Living with Dravet Syndrome

Epygenix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on using a highly predictive genetic screening platform to develop treatments for rare and intractable genetic epilepsies.

Our goal is to advance trailblazing treatments as quickly as possible. We are passionate about changing the way anti-seizure medications are discovered and developed.

Rare Genetic Epilepsy

Drug-resistant epilepsies with severe impact on patients and their families

Groundbreaking Platform

Innovative genetic screening platform backed by two decades of scientific research

Multi-Asset Pipeline

A multi-asset pipeline of promising preclinically validated drug candidates

Latest News

November 28, 2022

Epygenix Therapeutics to Present at the American Epilepsy Society 2022 Annual Meeting in Nashville

October 10, 2022

Epygenix Therapeutics to Host Investor Meetings at the 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum

Little Fish.
Big Potential.

A two-decade journey to find more effective epilepsy treatments all started with one little fish.

bottom of page